Logo

Alnylam Announces Pandemic Flu as Next Development Program; Gets DoD Funding

Dec 14, 2005

NEW YORK, Dec. 14 (GenomeWeb News) - With initial funding from the Department of Defense, Alnylam Pharmaceuticals will advance its pandemic flu project into a development program, the company announced today.

 

The project will join the pipeline of other RNAi therapeutics. The company expects to submit an investigational new drug application for an RNAi therapeutic for pandemic flu as early as the end of 2006.

 

The funding came from DoD's Defense Advanced Research Projects Agency, Alnylam said. The amount was not disclosed.

 

The Alnylam pandemic flu program is focused on the development of an RNAi therapeutic targeting sequences that are highly conserved across all flu genomes, including those of avian origin such as the H5N1 strain.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.